Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report)’s share price shot up 7.8% on Wednesday . The stock traded as high as $0.20 and last traded at $0.19. 19,100 shares changed hands during trading, a decline of 88% from the average session volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Stock Up 7.8 %
The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.86 and a current ratio of 2.86. The stock’s fifty day moving average is $0.19 and its 200-day moving average is $0.19.
About Vyant Bio
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
See Also
- Five stocks we like better than Vyant Bio
- How Investors Can Find the Best Cheap Dividend Stocks
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- How Do Stock Buybacks Affect Shareholders?
- Industrial Products Stocks Investing
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
